Oxford Nanopore
Auris Health
BJ Bioscience
GI Windows
Boundless Bio


Oxford Sciences Innovation (OSI)

Based in Oxford, England, Oxford Sciences Innovation (OSI) specializes in investments in spin-outs from Oxford University’s technology, mathematical, physical, life sciences and medical sciences departments.

Oxford Nanopore Technologies

Oxford Nanopore’s goal is to enable the analysis of any living thing, by anyone,anywhere. The Company has developed the world's first and only nanopore DNA sequencing platform, which is uniquely scalable from pocket-sized formats through to ultra-high throughput devices.

Oxford Investment Consultants LLP

Oxford Investment Consultants LLP is an investment advisor that covers life sciences, healthcare and technology in the United Kingdom. The firm prefers to make investments in the University of Oxford spin out companies. Oxford Investments Consultants LLP is based in the United Kingdom.

Latest information

Exscientia completes Series C financing round with BlackRock funds

Exscientia, a clinical stage pharmatech pioneering the use of artificial intelligence (AI) to design new drugs, today announced that funds managed by BlackRock joined the Company’s Series C investment round. The existing Series C investors also include Novo Holdings, Evotec, Bristol Myers Squibb, and GT Healthcare Capital.

Read more ›

Immunocore raises $258m in NASDAQ IPO

Immunocore’s upsized initial public offering in NASDAQ of 9,935,896 American Depositary Shares (“ADSs”) representing 9,935,896 ordinary shares at an initial public offering price of $26.00 per ADS, for total gross proceeds of approximately $258 million. The first day’s closing price jumps 66.15% to $43.2 per ADS, which represents a market cap of $1.796B. Immunocore is a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX - Immune mobilizing monoclonal TCRs Against X disease - designed to treat a broad range of diseases, including cancer, infectious and autoimmune. Immunocore's most advanced oncology therapeutic candidate, tebentafusp, demonstrates superior overall survival compared to investigator’s choice in a Phase 3 clinical trial of patients with previously untreated metastatic uveal melanoma.

Read more ›